滤泡性淋巴瘤-话题@MedSci

#滤泡性淋巴瘤#

69篇内容 | 4082人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1278806, encodeId=58bb12e8806fb, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=英国NICE推荐将来那度胺与利妥昔单抗联合用于治疗滤泡性淋巴瘤, objectType=article, longId=189157, objectId=3e3b18915ec7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e3b18915ec7, replyNumber=0, likeNumber=72, createdTime=2020-03-04, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e3b18915ec7, moduleTitle=英国NICE推荐将来那度胺与利妥昔单抗联合用于治疗滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e3b18915ec7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278805, encodeId=e97012e8805e0, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=TAZVERIK（tazemetostat）治疗滤泡性淋巴瘤：FDA已批准其NDA, objectType=article, longId=188196, objectId=741e188196b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=741e188196b9, replyNumber=0, likeNumber=80, createdTime=2020-02-17, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=741e188196b9, moduleTitle=TAZVERIK（tazemetostat）治疗滤泡性淋巴瘤：FDA已批准其NDA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=741e188196b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278804, encodeId=b72012e880444, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood：局限性和晚期滤泡性淋巴瘤的基因表达差异！, objectType=article, longId=187103, objectId=968118e10328, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=968118e10328, replyNumber=0, likeNumber=85, createdTime=2020-02-03, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=968118e10328, moduleTitle=Blood：局限性和晚期滤泡性淋巴瘤的基因表达差异！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=968118e10328)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278803, encodeId=cb4312e880360, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood：二代测序揭示N-糖基化位点对滤泡性淋巴瘤发生发展的重要作用, objectType=article, longId=186276, objectId=466e1862e624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=466e1862e624, replyNumber=0, likeNumber=80, createdTime=2020-01-16, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=466e1862e624, moduleTitle=Blood：二代测序揭示N-糖基化位点对滤泡性淋巴瘤发生发展的重要作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=466e1862e624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278802, encodeId=d87312e8802c5, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood：早期和晚期滤泡性淋巴瘤的基因表达差异, objectType=article, longId=181201, objectId=685a181201b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=685a181201b8, replyNumber=0, likeNumber=88, createdTime=2019-10-16, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=685a181201b8, moduleTitle=Blood：早期和晚期滤泡性淋巴瘤的基因表达差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=685a181201b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278801, encodeId=c2dd12e8801d3, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood：滤泡性淋巴瘤采用本达莫司汀联合利妥昔单抗治疗后早期病程进展提示高转化风险, objectType=article, longId=175624, objectId=7de11e562462, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7de11e562462, replyNumber=0, likeNumber=70, createdTime=2019-07-18, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7de11e562462, moduleTitle=Blood：滤泡性淋巴瘤采用本达莫司汀联合利妥昔单抗治疗后早期病程进展提示高转化风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7de11e562462)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278800, encodeId=e76712e8800ab, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood：BR治疗后早期进展与晚期滤泡性淋巴瘤的高转化风险相关, objectType=article, longId=175571, objectId=47bb1e5571e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47bb1e5571e8, replyNumber=0, likeNumber=88, createdTime=2019-07-17, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47bb1e5571e8, moduleTitle=Blood：BR治疗后早期进展与晚期滤泡性淋巴瘤的高转化风险相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47bb1e5571e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278799, encodeId=88f412e879981, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet Haematology：来那度胺联合Obinutuzumab单抗治疗复发或难治性滤泡性淋巴瘤, objectType=article, longId=175098, objectId=5aae1e5098dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5aae1e5098dd, replyNumber=0, likeNumber=67, createdTime=2019-07-11, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5aae1e5098dd, moduleTitle=Lancet Haematology：来那度胺联合Obinutuzumab单抗治疗复发或难治性滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5aae1e5098dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278798, encodeId=eca312e8798dd, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood cancer j：IGHV3-48基因的利用情况有望用于预测滤泡性淋巴瘤患者组织学转化的风险, objectType=article, longId=174984, objectId=d33d1e498434, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d33d1e498434, replyNumber=0, likeNumber=85, createdTime=2019-07-09, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d33d1e498434, moduleTitle=Blood cancer j：IGHV3-48基因的利用情况有望用于预测滤泡性淋巴瘤患者组织学转化的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d33d1e498434)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278797, encodeId=8d9112e87971d, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解, objectType=article, longId=173300, objectId=ce3d1e330034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce3d1e330034, replyNumber=0, likeNumber=98, createdTime=2019-06-28, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce3d1e330034, moduleTitle=Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce3d1e330034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278796, encodeId=53b112e879689, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=奥妥珠单抗有望成为滤泡性淋巴瘤患者治疗新的基石, objectType=article, longId=168969, objectId=d31216896904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d31216896904, replyNumber=0, likeNumber=144, createdTime=2019-06-24, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d31216896904, moduleTitle=奥妥珠单抗有望成为滤泡性淋巴瘤患者治疗新的基石, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d31216896904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278795, encodeId=4f3412e87955d, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=2018 JSH实践指南：血液恶性肿瘤—淋巴瘤：滤泡性淋巴瘤, objectType=article, longId=168199, objectId=46c416819912, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46c416819912, replyNumber=0, likeNumber=57, createdTime=2019-06-13, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46c416819912, moduleTitle=2018 JSH实践指南：血液恶性肿瘤—淋巴瘤：滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46c416819912)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278794, encodeId=40ca12e8794f5, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood：利妥昔单抗联合来那度胺作为一线疗法用于滤泡性淋巴瘤患者的疗效和安全性, objectType=article, longId=166325, objectId=1f1916632534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f1916632534, replyNumber=0, likeNumber=85, createdTime=2019-05-20, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f1916632534, moduleTitle=Blood：利妥昔单抗联合来那度胺作为一线疗法用于滤泡性淋巴瘤患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f1916632534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278793, encodeId=c4bb12e879322, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Cell Rep：科学家找到治疗滤泡性淋巴瘤的关键, objectType=article, longId=160892, objectId=d6671608928d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6671608928d, replyNumber=0, likeNumber=62, createdTime=2019-02-25, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6671608928d, moduleTitle=Cell Rep：科学家找到治疗滤泡性淋巴瘤的关键, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6671608928d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278792, encodeId=a0ef12e879210, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet Haematol：R-CHOP作为新确诊晚期滤泡性淋巴瘤患者一线治疗怎么样？, objectType=article, longId=155657, objectId=637315565e43, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=637315565e43, replyNumber=0, likeNumber=68, createdTime=2018-12-14, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=637315565e43, moduleTitle=Lancet Haematol：R-CHOP作为新确诊晚期滤泡性淋巴瘤患者一线治疗怎么样？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=637315565e43)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278791, encodeId=7bbf12e879189, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=JCO：利妥昔单抗时代滤泡性淋巴瘤死亡原因：队列汇总分析, objectType=article, longId=154619, objectId=34e2154619e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34e2154619e9, replyNumber=0, likeNumber=78, createdTime=2018-11-30, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34e2154619e9, moduleTitle=JCO：利妥昔单抗时代滤泡性淋巴瘤死亡原因：队列汇总分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34e2154619e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278790, encodeId=495812e879025, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood：以PET-CT分层可提高滤泡性淋巴瘤患者的放射治疗效果, objectType=article, longId=153807, objectId=a21f15380eae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a21f15380eae, replyNumber=0, likeNumber=86, createdTime=2018-11-19, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a21f15380eae, moduleTitle=Blood：以PET-CT分层可提高滤泡性淋巴瘤患者的放射治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a21f15380eae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278789, encodeId=f2b512e878994, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood：基因组变异情况可用于预测滤泡性淋巴瘤患者的预后, objectType=article, longId=153806, objectId=340d15380698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=340d15380698, replyNumber=0, likeNumber=78, createdTime=2018-11-19, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=340d15380698, moduleTitle=Blood：基因组变异情况可用于预测滤泡性淋巴瘤患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=340d15380698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278788, encodeId=bef012e878865, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet oncol：滤泡性淋巴瘤患者经一线免疫化疗后，以PET评估缓解情况的效果优于增强CT, objectType=article, longId=150640, objectId=75151506400f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75151506400f, replyNumber=0, likeNumber=70, createdTime=2018-10-11, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75151506400f, moduleTitle=Lancet oncol：滤泡性淋巴瘤患者经一线免疫化疗后，以PET评估缓解情况的效果优于增强CT, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75151506400f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278787, encodeId=d5a312e87879a, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=N Engl J Med:晚期滤泡性淋巴瘤：利妥昔单抗+来那度胺vs利妥昔单抗+化疗, objectType=article, longId=149892, objectId=952414989202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=952414989202, replyNumber=0, likeNumber=102, createdTime=2018-09-30, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=952414989202, moduleTitle=N Engl J Med:晚期滤泡性淋巴瘤：利妥昔单抗+来那度胺vs利妥昔单抗+化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=952414989202)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

滤泡性淋巴瘤

2020-05-29

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

英国NICE推荐将来那度胺与利妥昔单抗联合用于治疗滤泡性淋巴瘤

2020-03-04

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

TAZVERIK（tazemetostat）治疗滤泡性淋巴瘤：FDA已批准其NDA

2020-02-17

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood：局限性和晚期滤泡性淋巴瘤的基因表达差异！

2020-02-03

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood：二代测序揭示N-糖基化位点对滤泡性淋巴瘤发生发展的重要作用

2020-01-16

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood：早期和晚期滤泡性淋巴瘤的基因表达差异

2019-10-16

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood：滤泡性淋巴瘤采用本达莫司汀联合利妥昔单抗治疗后早期病程进展提示高转化风险

2019-07-18

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood：BR治疗后早期进展与晚期滤泡性淋巴瘤的高转化风险相关

2019-07-17

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Lancet Haematology：来那度胺联合Obinutuzumab单抗治疗复发或难治性滤泡性淋巴瘤

2019-07-11

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood cancer j：IGHV3-48基因的利用情况有望用于预测滤泡性淋巴瘤患者组织学转化的风险

2019-07-09

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解

2019-06-28

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

奥妥珠单抗有望成为滤泡性淋巴瘤患者治疗新的基石

2019-06-24

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

2018 JSH实践指南：血液恶性肿瘤—淋巴瘤：滤泡性淋巴瘤

2019-06-13

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood：利妥昔单抗联合来那度胺作为一线疗法用于滤泡性淋巴瘤患者的疗效和安全性

2019-05-20

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Cell Rep：科学家找到治疗滤泡性淋巴瘤的关键

2019-02-25

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Lancet Haematol：R-CHOP作为新确诊晚期滤泡性淋巴瘤患者一线治疗怎么样？

2018-12-14

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

JCO：利妥昔单抗时代滤泡性淋巴瘤死亡原因：队列汇总分析

2018-11-30

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood：以PET-CT分层可提高滤泡性淋巴瘤患者的放射治疗效果

2018-11-19

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood：基因组变异情况可用于预测滤泡性淋巴瘤患者的预后

2018-11-19

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Lancet oncol：滤泡性淋巴瘤患者经一线免疫化疗后，以PET评估缓解情况的效果优于增强CT

2018-10-11

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

N Engl J Med:晚期滤泡性淋巴瘤：利妥昔单抗+来那度胺vs利妥昔单抗+化疗

2018-09-30

科室
- - 订阅+
  - 更多科室
工具
服务